Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Non Operating Income (2018 - 2023)

Rapid Therapeutic Science Laboratories' Non Operating Income history spans 6 years, with the latest figure at $150154.0 for Q2 2023.

  • For Q2 2023, Non Operating Income rose 64.04% year-over-year to $150154.0; the TTM value through Jun 2023 reached $607147.0, up 144.2%, while the annual FY2022 figure was -$531393.0, 23.21% up from the prior year.
  • Non Operating Income for Q2 2023 was $150154.0 at Rapid Therapeutic Science Laboratories, down from $289565.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $289565.0 in Q1 2023 and bottomed at -$790358.0 in Q1 2022.
  • The 5-year median for Non Operating Income is -$19696.5 (2020), against an average of -$63354.2.
  • The largest YoY upside for Non Operating Income was 2866.3% in 2022 against a maximum downside of 5628.06% in 2022.
  • A 5-year view of Non Operating Income shows it stood at -$34823.0 in 2019, then surged by 51.78% to -$16792.0 in 2020, then tumbled by 3399.09% to -$587567.0 in 2021, then soared by 103.68% to $21597.0 in 2022, then skyrocketed by 595.25% to $150154.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Non Operating Income are $150154.0 (Q2 2023), $289565.0 (Q1 2023), and $21597.0 (Q4 2022).